Richard Eiswirth Net Worth

The estimated Net Worth of Richard S Jr Eiswirth is at least $1.62 Миллион dollars as of 15 December 2021. Mr. Eiswirth owns over 484 units of Alimera Sciences stock worth over $611,165 and over the last 15 years he sold ALIM stock worth over $33,920. In addition, he makes $977,025 as President, Chief Executive Officer и Director at Alimera Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Eiswirth ALIM stock SEC Form 4 insiders trading

Richard has made over 17 trades of the Alimera Sciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 484 units of ALIM stock worth $2,178 on 15 December 2021.

The largest trade he's ever made was exercising 51,471 units of Alimera Sciences stock on 15 September 2016 worth over $68,456. On average, Richard trades about 5,609 units every 76 days since 2010. As of 15 December 2021 he still owns at least 110,518 units of Alimera Sciences stock.

You can see the complete history of Mr. Eiswirth stock trades at the bottom of the page.

Richard Eiswirth biography

Richard S. Eiswirth Jr. serves as President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer since January 2019. Mr. Eiswirth had previously served as our President and Chief Financial Officer since January 2016. Before that, he served as our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a public provider of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based public manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University. The Board believes that Mr. Eiswirth should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to the Company in recent years, his background as a CPA, his previous service as our President, Chief Operating Officer and Chief Financial Officer, and his experience as chairman of the board of directors and audit committee chairman of other companies.

What is the salary of Richard Eiswirth?

As the President, Chief Executive Officer и Director of Alimera Sciences, the total compensation of Richard Eiswirth at Alimera Sciences is $977,025. There are no executives at Alimera Sciences getting paid more.

How old is Richard Eiswirth?

Richard Eiswirth is 51, he's been the President, Chief Executive Officer и Director of Alimera Sciences since 2019. There are 13 older and 2 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.

What's Richard Eiswirth's mailing address?

Richard's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, , ALPHARETTA, GA, 30005.

Insiders trading at Alimera Sciences

Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo и Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.

What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Complete history of Mr. Eiswirth stock trades at Alimera Sciences

Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include:

• Richard Eiswirth,
  President, Chief Executive Officer, Director
• C. Daniel Myers,
  Non-Executive Chairman of the Board
• Richard S. Eiswirth Jr.,
  Pres, CEO & Director
• David Holland,
  Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets
• Philip Ashman,
  Chief Operating Officer, Senior Vice President - Commercial Operations Europe
• David R. Holland,
  Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
• Dr. Philip Ashman,
  COO & Sr. VP of Commercial Operations - Europe
• Charles Daniel Myers,
  Non-Exec. Chairman & Consultant
• James Largent,
  Lead Independent Director
• John Marco,
  Investor Relations
• Mary Szela,
  Independent Director
• John Snisarenko,
  Independent Director
• Peter Pizzo,
  Independent Director
• Garheng Kong,
  Independent Director
• Brian Halak,
  Independent Director
• Samer Kaba,
  Chief Medical Officer
• Phil Jones,
  Chief Financial Officer
• Dr. David Dyer,
  Chief Retina Specialist
• Christopher S. Visick,
  VP, Gen. Counsel & Sec.
• J. Philip Jones,
  Chief Financial Officer
• Calvin W. Roberts,
  Director
• Glen Bradley,
  Director
• James E Deerfield Mgmt L.P....,
  
• Mark J Brooks,
  Director
• Kenneth Green,
  SVP & Chief Scientific Officer
• L.P.Mitchell Kateo'driscoll...,
  
• Alto Investors Lp Palo,
  
• Russell Skibsted,
  Chief Financial Officer & SVP
• Capital, Llc Armistice Capi...,
  
• Patrick Lee,
  10% owner
• Management Viii, L.L.C.Sofi...,
  
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Jesse I Treu,
  10% owner
• Venture Management Co Iv Ll...,
  
• Philip R Tracy,
  Director
• Susan Caballa,
  SEE REMARKS
• Kathleen K Schoemaker,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• Nicole Vitullo,
  10% owner
• Anders D Hove,
  Director
• Bryce Youngren,
  Director
• Brian H Dovey,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Associates Iv L P Venrock M...,
  
• Associates Vi, Llc Mumma Mi...,
  
• Associates Vii, Llc Mumma M...,
  
• Associates V, Llc Mumma Mit...,
  
• L.P.Bock Louis Cmitchell Ka...,
  
• Adam Morgan,
  Director
• Stanley Morgan,
  10% owner
• Todd Michael Wood,
  President of U.S. Operations
• Roger Sawhney,
  Director
• Adam Velan Capital Investme...,
  
• Partners Lpjohnson David Ed...,
  
• Jason M. Werner,
  Chief Operating Officer
• Erin Parsons,
  
• Michael Kaseta,
  
• Ross D De Mont,
  
• Margaret Pax,
  
• Elliot Maltz,
  Chief Financial Officer